EcoDrugPlus

Matrix Metallopeptidase 9

Ensembl ID : ENSRFEG00010017975
Gene Symbol: MMP9
1 Cross references
214 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSRFEG00010015400
Gene Symbol: MTOR
1 Cross references
214 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSRFEG00010011233
Gene Symbol: MC1R
1 Cross references
159 Possible Orthologues:

Melanocortin 3 Receptor

Ensembl ID : ENSRFEG00010021575
Gene Symbol: MC3R
1 Cross references
138 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSRFEG00010012505
Gene Symbol: MC4R
1 Cross references
121 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSRFEG00010012919
Gene Symbol: MTNR1A
1 Cross references
205 Possible Orthologues:

Melatonin Receptor 1b

Ensembl ID : ENSRFEG00010018917
Gene Symbol: MTNR1B
1 Cross references
107 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSRFEG00010005413
Gene Symbol: MME
1 Cross references
235 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSRFEG00010000487
Gene Symbol: METAP2
1 Cross references
214 Possible Orthologues:

Microtubule Associated Protein Tau

Ensembl ID : ENSRFEG00010008834
Gene Symbol: MAPT
1 Cross references
255 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSRFEG00010017785
Gene Symbol: MAPK1
1 Cross references
213 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSRFEG00010003450
Gene Symbol: MAPK10
1 Cross references
147 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).